Becton Dickinson & Co

Spikner’s 84‑share sale at Becton Dickinson is a routine tax‑related RSU vesting move—no strategic signal, just liquidity management. Investors see stability and long‑term growth potential.

BD insider trades reveal confidence amid FDA‑cleared EnCompass biopsy system & syringe expansion—key insights for clinicians and investors.